Want to create an interactive transcript for this episode?
Podcast: Surfing the MASH Tsunami
Episode: S3-E48.4 - Promising Interim Data from Axcella’s Phase 2B EMMPACT Study
Description: A recent string of press releases presaged some of the most exciting, promising data of the last decade in NASH drug development. In this conversation, the panel continues exploring oral drugs (specifically PXL-065) before reviewing positive interim data from the Phase 2b EMMPACT study by Axcella. Roger Green notes that introducing multiple modes of action to the market will create the energy and investment to drive a dynamic explosion of education and exploration in Fatty Liver diseases. Stephen Harrison adds final thoughts on why PXL-065 may be a good choice in combination and/or long-term maintenance therapy. T...